Gilead of­floads a PhII-ready ad­dic­tion ther­a­py to an up­start which knows this drug well

Eight years ago, Gilead snapped up CV Ther­a­peu­tics and its angi­na drug Ranexa for $1.4 bil­lion, look­ing to beef up its port­fo­lio of car­dio drugs. But one of the as­sets it picked up, an ALDH-2 in­hibitor dubbed GS-6637, nev­er made it far in the clin­ic.

Test­ed for drug ad­dic­tion, it cleared Phase I and sat at the bot­tom of Gilead’s pipeline for liv­er dis­ease.

Now, though, a group of those ex-CV ex­ecs have come back to­geth­er to cre­ate Amyg­dal­la Neu­ro­sciences and went back to Gilead to pick up the as­set with plans to get in­to a Phase II study.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER